Diabetic macular edema (DME)

Diabetic macular edema (DME):

Diabetic macular edema (DME) is a serious complication of diabetic retinopathy, a condition caused by damage to the blood vessels in the retina due to diabetes. In DME, fluid accumulates in the macula, the central part of the retina responsible for sharp, central vision. This buildup of fluid can cause the macula to swell, leading to vision distortion and potentially severe vision loss if left untreated. Diagnosis of DME typically involves a comprehensive eye examination by an ophthalmologist, including optical coherence tomography (OCT) imaging to assess macular thickness and the extent of edema, as well as fluorescein angiography to evaluate blood flow in the retina.

The Retyne Infrared Eye Treatment Mask offers a promising therapeutic option for managing the symptoms of Diabetic macular edema (DME). Program #5 on the Retyne controller is specifically designed to target the underlying mechanisms of DME, leveraging a combination of infrared frequencies known for their anti-inflammatory and tissue-regenerating properties. By delivering these frequencies directly to the affected eye, the Retyne mask can help reduce inflammation, promote fluid reabsorption, and improve retinal function, thereby alleviating symptoms such as blurred vision and distortion. This non-invasive and convenient treatment approach can complement existing therapies for DME, offering patients an effective option to enhance their visual outcomes and quality of life.

The Retyne Infrared Eye Treatment Mask not only delivers therapeutic benefits but also ensures a safe and comfortable experience for individuals dealing with Diabetic macular edema (DME). Through the utilization of invisible infrared light, this treatment modality offers a gentle yet effective approach, allowing patients to receive treatment without any discomfort or inconvenience. Moreover, its at-home usability adds to the convenience, enabling long-term management of DME symptoms from the comfort of one's own home. With its precisely targeted approach and user-friendly design, the Retyne mask emerges as an invaluable asset in the holistic care of individuals battling DME, promising not only relief from symptoms but also optimism for improved vision and better outcomes in combating this serious eye condition.

The Retyne eye treatment mask harnesses a series of frequencies (0.15, 0.89, 1.7, 6.97, 12.89, 62.3, 421, 465, 895, 951.3 ) specifically tailored for addressing Diabetic macular edema (DME). These frequencies have been carefully selected for their efficacy in managing and treating this condition.

Retyne's approach involves translating each frequency into invisible infrared light output, representing a novel integration of frequencies with light, a pioneering technology developed by Retyne Labs. This innovative method draws inspiration from the pioneering work of Dr. Rife, who identified specific frequencies with healing properties and utilized a light source for their transmission. Building upon current research on invisible infrared technology and leveraging past studies on light transmission via frequency sources, the Retyne eye treatment mask represents a fusion of cutting-edge advancements in the field.

Diabetic macular edema (DME) frequencies exist at program 1229 on the International ETDFL frequency list